Skip to Content

Current Oncology, Volume 28, Issue 2

2021 April - 48 articles

Cover Story: This overview of all randomized controlled trials (RCTs) published globally shows that Canada plays a meaningful role in the international cancer research community. Canadian RCTs are heavily dependent on funding from the pharmaceutical industry and primarily test new systemic therapies in the palliative context. Only one third of positive Canadian trials (and 13% of all trials) identify a new treatment that is associated with substantial clinical benefit; therefore, urgent efforts to improve on this are warranted. It is notable that only 14% of Canadian trials are conducted without industry funding. These data highlight the need for more investment in cancer clinical trials from the government and philanthropic sectors to ensure that Canadian RCTs address diseases and questions that are most likely to improve outcomes for patients in Canada and beyond. View this paper
  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
  • You may sign up for email alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (48)

  • Case Report
  • Open Access
7 Citations
4,004 Views
7 Pages

Regression of Intracranial Meningiomas Following Treatment with Cabozantinib

  • Rupesh Kotecha,
  • Raees Tonse,
  • Haley Appel,
  • Yazmin Odia,
  • Ritesh R. Kotecha,
  • Guilherme Rabinowits and
  • Minesh P. Mehta

18 April 2021

Recurrent meningiomas remain a substantial treatment challenge given the lack of effective therapeutic options aside from surgery and radiation therapy, which yield limited results in the retreatment situation. Systemic therapies have little effect,...

  • Article
  • Open Access
12 Citations
4,702 Views
14 Pages

The Epidemiology of Myeloproliferative Neoplasms in New Zealand between 2010 and 2017: Insights from the New Zealand Cancer Registry

  • Chris Varghese,
  • Tracey Immanuel,
  • Anna Ruskova,
  • Edward Theakston and
  • Maggie L. Kalev-Zylinska

18 April 2021

Background: There is a paucity of data on ethnic disparities in patients with the classical Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs): polycythaemia vera (PV), essential thrombocythaemia (ET) and primary myelofibrosis (PMF)...

  • Article
  • Open Access
1 Citations
4,141 Views
10 Pages

Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials

  • Shubham Sharma,
  • J. Connor Wells,
  • Wilma M. Hopman,
  • Joseph C. Del Paggio,
  • Bishal Gyawali,
  • Nazik Hammad,
  • Annette E. Hay and
  • Christopher M. Booth

13 April 2021

Canada has a long tradition of leading practice-changing clinical trials in oncology. Here, we describe methodology, results, and interpretation of oncology RCTs with Canadian involvement compared to RCTs from other high-income countries (HICs). A li...

  • Article
  • Open Access
9 Citations
2,695 Views
9 Pages

13 April 2021

Purpose: We assessed clinical and tumor biological features and evaluated their association with positive surgical margins (PSMs) and positive apical margins (PAMs) variability after radical prostatectomy (RP) in men with non-metastasis prostate canc...

  • Article
  • Open Access
13 Citations
3,887 Views
11 Pages

Satisfaction among Cancer Patients Undergoing Radiotherapy during the COVID-19 Pandemic: An Institutional Experience

  • Vanessa Di Lalla,
  • Haley Patrick,
  • Nicolas Siriani-Ayoub,
  • John Kildea,
  • Tarek Hijal and
  • Joanne Alfieri

10 April 2021

The COVID-19 pandemic has shifted oncology practices to prioritize patient safety while maintaining necessary treatment delivery. We obtained patient feedback on pandemic-based practices in our radiotherapy department to improve quality of patient ca...

  • Article
  • Open Access
5 Citations
3,686 Views
11 Pages

Healthcare Provider Perspectives on Adherence to Adjuvant Endocrine Therapy after Breast Cancer

  • Leah K. Lambert,
  • Lynda G. Balneaves,
  • A. Fuchsia Howard,
  • Stephen L. K. Chia and
  • Carolyn C. Gotay

9 April 2021

Adherence to adjuvant endocrine therapy (AET) for breast cancer is suboptimal. The purpose of this study was to: (1) explore the experiences and perspectives of healthcare providers (HCPs) in providing care to breast cancer survivors prescribed AET,...

  • Article
  • Open Access
13 Citations
4,059 Views
12 Pages

Oncology Clinicians’ Challenges to Providing Palliative Cancer Care—A Theoretical Domains Framework, Pan-Cancer System Survey

  • Sharlette Dunn,
  • Madelene A. Earp,
  • Patricia Biondo,
  • Winson Y. Cheung,
  • Marc Kerba,
  • Patricia A. Tang,
  • Aynharan Sinnarajah,
  • Sharon M. Watanabe and
  • Jessica E. Simon

9 April 2021

Despite the known benefits, healthcare systems struggle to provide early, integrated palliative care (PC) for advanced cancer patients. Understanding the barriers to providing PC from the perspective of oncology clinicians is an important first step...

  • Article
  • Open Access
27 Citations
5,357 Views
12 Pages

9 April 2021

Introduction: Venous access is a crucial element in chemotherapy delivery. It remains unclear whether cancer patients prefer a port to a peripherally inserted central catheter (PICC). Our study aimed to assess cancer patients’ satisfaction with their...

  • Guidelines
  • Open Access
6 Citations
5,434 Views
12 Pages

Patient and Patient Group Engagement in Cancer Clinical Trials: A Stakeholder Charter

  • Stéphanie Michaud,
  • Judy Needham,
  • Stephen Sundquist,
  • Dominique Johnson,
  • Sabrina Hanna,
  • Sharareh Hosseinzadeh,
  • Vatche Bartekian,
  • Patricia Steele,
  • Sarita Benchimol and
  • Barry D. Stein
  • + 1 author

8 April 2021

Background—to guide the implementation of patient centricity and engagement in cancer clinical trials (CTs) and to operationalize the Canadianized version of the Clinical Trials Transformation Initiative (C-CTTI) model, the development of a charter w...

  • Article
  • Open Access
23 Citations
3,539 Views
13 Pages

A Comparison of Patient-Reported Outcomes Following Consent for Genetic Testing Using an Oncologist- or Genetic Counselor-Mediated Model of Care

  • Jeanna M. McCuaig,
  • Emily Thain,
  • Janet Malcolmson,
  • Sareh Keshavarzi,
  • Susan Randall Armel and
  • Raymond H. Kim

8 April 2021

This study compares knowledge, experience and understanding of genetic testing, and psychological outcomes among breast and ovarian cancer patients undergoing multi-gene panel testing via genetic counselor-mediated (GMT) or oncologist-mediated (OMT)...

  • Article
  • Open Access
5 Citations
3,071 Views
13 Pages

Benefit from Adjuvant TKIs Versus TKIs Plus Chemotherapy in EGFR-Mutant Stage III-pN2 Lung Adenocarcinoma

  • Qiwen Li,
  • Li Ma,
  • Bo Qiu,
  • Yuzhi Wen,
  • Wenhua Liang,
  • Wanming Hu,
  • Naibin Chen,
  • Tian Zhang,
  • Shuangbing Xu and
  • Hui Liu
  • + 10 authors

7 April 2021

Background: Recent studies have demonstrated benefits from adjuvant tyrosine-kinase inhibitors (TKIs) compared with chemotherapy in non-small cell lung cancer. We launched a multi-center retrospective study to evaluate the efficacy and toxicity of ad...

  • Article
  • Open Access
13 Citations
3,372 Views
10 Pages

On the Prognosis of Multifocal Glioblastoma: An Evaluation Incorporating Volumetric MRI

  • Johannes Kasper,
  • Nicole Hilbert,
  • Tim Wende,
  • Michael Karl Fehrenbach,
  • Florian Wilhelmy,
  • Katja Jähne,
  • Clara Frydrychowicz,
  • Gordian Hamerla,
  • Jürgen Meixensberger and
  • Felix Arlt

7 April 2021

Primary glioblastoma (GBM), IDH-wildtype, especially with multifocal appearance/growth (mGBM), is associated with very poor prognosis. Several clinical parameters have been identified to provide prognostic value in both unifocal GBM (uGBM) and mGBM,...

  • Review
  • Open Access
23 Citations
5,574 Views
12 Pages

Impact of Metformin on Cancer Biomarkers in Non-Diabetic Cancer Patients: A Systematic Review and Meta-Analysis of Clinical Trials

  • Tahereh Farkhondeh,
  • Alireza Amirabadizadeh,
  • Hamed Aramjoo,
  • Silvia Llorens,
  • Babak Roshanravan,
  • Farhad Saeedi,
  • Marjan Talebi,
  • Mehdi Shakibaei and
  • Saeed Samarghandian

6 April 2021

Introduction: Our aim was to investigate and evaluate the influence of metformin on cancer-related biomarkers in clinical trials. Methods: This systematic study was conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Anal...

  • Article
  • Open Access
19 Citations
3,815 Views
10 Pages

Efficacy and Safety of Nivolumab and Ipilimumab for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study

  • Koji Iinuma,
  • Koji Kameyama,
  • Kei Kawada,
  • Shota Fujimoto,
  • Kimiaki Takagi,
  • Shingo Nagai,
  • Hiroki Ito,
  • Takashi Ishida,
  • Makoto Kawase and
  • Takuya Koie
  • + 5 authors

3 April 2021

We conducted a multicenter, retrospective study to evaluate the efficacy and safety of combination nivolumab plus ipilimumab (NIVO+IPI) in 35 patients with advanced or metastatic renal cell carcinoma (mRCC). In this study, we focused on patients who...

  • Article
  • Open Access
12 Citations
5,942 Views
12 Pages

Consensus Recommendations for MRD Testing in Adult B-Cell Acute Lymphoblastic Leukemia in Ontario

  • Anne Tierens,
  • Tracy L. Stockley,
  • Clinton Campbell,
  • Jill Fulcher,
  • Brian Leber,
  • Elizabeth McCready,
  • Peter J. B. Sabatini,
  • Bekim Sadikovic and
  • Andre C. Schuh

30 March 2021

Measurable (minimal) residual disease (MRD) is an established, key prognostic factor in adult B-cell acute lymphoblastic leukemia (B-ALL), and testing for MRD is known to be an important tool to help guide treatment decisions. The clinical value of M...

  • Article
  • Open Access
7 Citations
3,174 Views
14 Pages

Current Treatment Approaches and Outcomes in the Management of Rectal Cancer Above the Age of 80

  • Ali P. Mourad,
  • Marie Shella De Robles,
  • Soni Putnis and
  • Robert D.R. Winn

30 March 2021

Background: The number of cases of rectal cancer in our older cohort is expected to rise with our ageing population. In this study, we analysed patterns in treatment and the long-term outcomes of patients older than 80 years with rectal cancer across...

  • Article
  • Open Access
9 Citations
2,849 Views
12 Pages

The Impact of Radiotherapy Dose in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma Receiving Preoperative Chemoradiotherapy

  • Chien-Ming Lo,
  • Yu-Ming Wang,
  • Yen-Hao Chen,
  • Fu-Min Fang,
  • Shun-Chen Huang,
  • Hung-I Lu and
  • Shau-Hsuan Li

29 March 2021

Objective: For patients with esophageal squamous cell carcinoma, preoperative chemoradiotherapy followed by planned esophagectomy is used as a curative treatment modality. However, the impact of radiotherapy dose remains undefined. Method: A total of...

  • Article
  • Open Access
2 Citations
2,626 Views
10 Pages

29 March 2021

Variation in the management of Ductal Carcinoma In Situ (DCIS) of the breast occur at both national and international levels. The aim of this study is to determine the degree of, and reasons behind, this variation in the workup and treatment of DCIS...

  • Case Report
  • Open Access
5 Citations
3,301 Views
6 Pages

27 March 2021

The coronavirus disease 2019 (COVID-19) pandemic has had a substantial impact on the provision of medical healthcare. Due to an increased risk of severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) transmission, elective surgical treatment h...

  • Review
  • Open Access
19 Citations
4,681 Views
10 Pages

Neoadjuvant Chemotherapy in Breast Cancer: Review of the Evidence and Conditions That Facilitated Its Use during the Global Pandemic

  • Tabitha Tse,
  • Sandeep Sehdev,
  • Jean Seely,
  • Denis H. Gravel,
  • Mark Clemons,
  • Erin Cordeiro and
  • Angel Arnaout

24 March 2021

Practice and behaviour change in healthcare is complex, and requires a set of critical steps that would be needed to implement and sustain the change. Neoadjuvant chemotherapy for breast cancer is traditionally used for locally advanced disease and i...

  • Article
  • Open Access
25 Citations
4,110 Views
13 Pages

Body Composition as a Predictor of Toxicity and Prognosis in Patients with Diffuse Large B-Cell Lymphoma Receiving R-CHOP Immunochemotherapy

  • Jiaxun Guo,
  • Panpan Cai,
  • Pengfei Li,
  • Cong Cao,
  • Jing Zhou,
  • Lina Dong,
  • Yan Yang,
  • Qijia Xuan,
  • Jingxuan Wang and
  • Qingyuan Zhang

23 March 2021

Background: Our study measured the body composition of Diffuse large B-cell lymphoma (DLBCL) patients receiving rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) regimen by computed tomographic (CT) and assessed their...

  • Article
  • Open Access
9 Citations
3,166 Views
8 Pages

22 March 2021

This study aimed to determine the predictive value of the Prostate Imaging Reporting and Data System version 2 (PI-RADS v2) based on biparametric magnetic resonance imaging (bpMRI) with combined target biopsy (TBx) and systematic biopsy (SBx) in pati...

  • Systematic Review
  • Open Access
9 Citations
3,446 Views
12 Pages

The Role of Denosumab for Surgical Outcomes in Patients with Giant Cell Tumour of Bone: A Systematic Review

  • Abha Gupta,
  • Lisa Durocher-Allen,
  • Snezana Popovic,
  • Richard Tozer,
  • Xiaomei Yao and
  • Michelle Ghert

22 March 2021

Background: The role of denosumab in patients with resectable giant cell tumour of bone remains unclear. We asked the following research question: for patients (aged ≥ 12 years) with resectable giant cell tumour of bone, what are the benefits and har...

  • Article
  • Open Access
12 Citations
3,392 Views
11 Pages

22 March 2021

The present study aimed to elucidate the clinicopathological significance and prognostic implications of tumor–stroma ratio (TSR) in colorectal cancers (CRCs). TSRs were investigated in 266 human CRC specimens. The correlations between TSR and clinic...

  • Article
  • Open Access
6 Citations
3,163 Views
14 Pages

The Influence of Gene Aberrations on Survival in Resected IDH Wildtype Glioblastoma Patients: A Single-Institution Study

  • Ondrej Kalita,
  • Zuzana Sporikova,
  • Marian Hajduch,
  • Magdalena Megova Houdova,
  • Rastislav Slavkovsky,
  • Lumir Hrabalek,
  • Matej Halaj,
  • Yvona Klementova,
  • Martin Dolezel and
  • Miroslav Vaverka
  • + 5 authors

21 March 2021

This prospective population-based study on a group of 132 resected IDH-wildtype (IDH-wt) glioblastoma (GBM) patients assesses the prognostic and predictive value of selected genetic biomarkers and clinical factors for GBM as well as the dependence of...

  • Case Report
  • Open Access
10 Citations
3,965 Views
6 Pages

PTEN R130Q Papillary Tumor of the Pineal Region (PTPR) with Chromosome 10 Loss Successfully Treated with Everolimus: A Case Report

  • Hazem I. Assi,
  • Rasha T. Kakati,
  • Juliett Berro,
  • Ibrahim Saikali,
  • Bassem Youssef,
  • Roula Hourany,
  • Ibrahim Alameh,
  • Abeer Tabbarah,
  • Jessica Khoury and
  • Saada Alame
  • + 1 author

20 March 2021

Papillary tumors of the pineal region (PTPR) can be observed among adults with poor prognosis and high recurrence rates. Standards of therapy involve total surgical excision along with radiation therapy, with no promising prospects for primary adjuva...

  • Brief Report
  • Open Access
3 Citations
3,224 Views
6 Pages

Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial

  • Anca Prica,
  • Annette E. Hay,
  • Michael Crump,
  • Nicole Mittmann,
  • Lois E. Shepherd,
  • Ralph M. Meyer,
  • Kevin I. Imrie,
  • Nancy Risebrough,
  • Marina Djurfeldt and
  • Matthew C. Cheung
  • + 1 author

17 March 2021

We conducted an analysis of indirect costs alongside the LY.12 randomized trial in patients with relapsed or refractory (R/R) aggressive non-Hodgkin lymphoma (NHL). Lost productivity data for Canadian patients and caregivers in the trial were collect...

  • Article
  • Open Access
3 Citations
3,204 Views
12 Pages

Comparison of Perioperative Chemotherapy versus Postoperative Chemoradiotherapy for Operable Stomach Cancer: A Western Canadian Province Experience

  • Adnan Zaidi,
  • Amal Khan,
  • Claire Duval,
  • Kamal Haider,
  • Osama Ahmed,
  • Dorie-Anna Dueck,
  • Bryan Brunet,
  • Donald Gardiner and
  • Shahid Ahmed

17 March 2021

Background: The standard approaches for resectable stomach cancer are postoperative chemoradiotherapy (PCR) or perioperative chemotherapy (PC). Limited evidence is available regarding the superiority of one of the two approaches. We aimed to compare...

  • Article
  • Open Access
1 Citations
3,328 Views
7 Pages

Multicenter Study of the Seroprevalence of Antibodies against Covid-19 in Patients with Lymphoma: An Analysis of the Oncological Group for the Treatment and Study of Lymphomas (Gotel)

  • Fernando Franco,
  • María Guirado,
  • Natividad Martínez-Banaclocha,
  • Josep Gumà,
  • Javier Lavernia,
  • José Gómez-Codina,
  • Delvys Rodriguez-Abreu,
  • Fani Martínez,
  • Enrique Barrajón and
  • Mariano Provencio
  • + 2 authors

16 March 2021

The new Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) coronavirus has generated a pandemic, in which there are population groups at higher risk and who are potentially fatal victims of the disease. Cancer patients have been considered...

  • Article
  • Open Access
9 Citations
3,320 Views
12 Pages

Circulating miR-618 Has Prognostic Significance in Patients with Metastatic Colon Cancer

  • Maria Radanova,
  • Galya Mihaylova,
  • Zhasmina Mihaylova,
  • Desislava Ivanova,
  • Oskan Tasinov,
  • Neshe Nazifova-Tasinova,
  • Pavel Pavlov,
  • Milko Mirchev,
  • Nikolay Conev and
  • Ivan Donev

15 March 2021

The present study evaluated the prognostic role of circulating miRNA-618 in patients with metastatic colon cancer (mCC) and whether miR-618 gene rs2682818 single nucleotide polymorphisms (SNP) are associated with colon cancer susceptibility and expre...

  • Systematic Review
  • Open Access
161 Citations
16,244 Views
33 Pages

The Out-of-Pocket Cost Burden of Cancer Care—A Systematic Literature Review

  • Nicolas Iragorri,
  • Claire de Oliveira,
  • Natalie Fitzgerald and
  • Beverley Essue

15 March 2021

Background: Out-of-pocket costs pose a substantial economic burden to cancer patients and their families. The purpose of this study was to evaluate the literature on out-of-pocket costs of cancer care. Methods: A systematic literature review was cond...

  • Article
  • Open Access
10 Citations
3,343 Views
7 Pages

14 March 2021

Tobacco cessation has been recognized as an important goal for all ambulatory cancer centres to provide the best possible treatment outcomes and quality of life. However, cessation interventions are applied inconsistently in this setting, with less t...

  • Article
  • Open Access
4 Citations
5,020 Views
14 Pages

Restructuring Skin Cancer Care in Ontario: A Provincial Plan

  • John Milkovich,
  • Tim Hanna,
  • Carolyn Nessim,
  • Teresa M. Petrella,
  • Louis Weatherhead,
  • An-Wen Chan,
  • Jonathan C. Irish,
  • Christian Murray,
  • Grace Bannerman and
  • the Ontario Skin Cancer Advisory Committee
  • + 4 authors

12 March 2021

There is a global rise in skin cancer incidence, resulting in an increase in patient care needs and healthcare costs. To optimize health care planning, costs, and patient care, Ontario Health developed a provincial skin cancer plan to streamline the...

  • Article
  • Open Access
19 Citations
7,380 Views
13 Pages

The Relationship between Fatigue and Actigraphy-Derived Sleep and Rest–Activity Patterns in Cancer Survivors

  • Tristan Martin,
  • Rosie Twomey,
  • Mary E. Medysky,
  • John Temesi,
  • S. Nicole Culos-Reed and
  • Guillaume Y. Millet

10 March 2021

Cancer-related fatigue can continue long after curative cancer treatment. The aim of this study was to investigate sleep and rest–activity cycles in fatigued and non-fatigued cancer survivors. We hypothesized that sleep and rest–activity cycles would...

  • Article
  • Open Access
6 Citations
2,887 Views
8 Pages

A Canadian Prospective Study of Linkage of Randomized Clinical Trial to Cancer and Mortality Registry Data

  • Annette E Hay,
  • Nicole Mittmann,
  • Michael Crump,
  • Matthew C Cheung,
  • Jessica Sleeth,
  • Judy Needham,
  • Mike Broekhoven,
  • Marina Djurfeldt,
  • Lois E Shepherd and
  • Joseph L Pater
  • + 2 authors

8 March 2021

In a prospective study, we sought to determine acceptability of linkage of administrative and clinical trial data among Canadian patients and Research Ethics Boards (REBs). The goal is to develop a more harmonized approach to data, with potential to...

  • Case Report
  • Open Access
7 Citations
3,416 Views
9 Pages

Identification and In-Depth Analysis of the Novel FGFR2-NDC80 Fusion in a Cholangiocarcinoma Patient: Implication for Therapy

  • Alexander Scheiter,
  • Felix Keil,
  • Florian Lüke,
  • Jirka Grosse,
  • Niklas Verloh,
  • Sabine Opitz,
  • Sophie Schlosser,
  • Arne Kandulski,
  • Tobias Pukrop and
  • Kirsten Utpatel
  • + 3 authors

8 March 2021

Fibroblast growth factor receptor 2 (FGFR2) fusions have emerged as a new therapeutic target for cholangiocarcinoma in clinical practice following the United States Food and Drug Administration (FDA) approval of Pemigatinib in May 2020. FGFR2 fusions...

  • Article
  • Open Access
13 Citations
3,234 Views
10 Pages

Management of the Elderly Patients with High-Grade Serous Ovarian Cancer in the REAL-WORLD Setting

  • Michalis Liontos,
  • Alkistis Papatheodoridi,
  • Angeliki Andrikopoulou,
  • Nikolaos Thomakos,
  • Dimitrios Haidopoulos,
  • Alexandros Rodolakis,
  • Flora Zagouri,
  • Aristotelis Bamias and
  • Meletios-Athanasios Dimopoulos

7 March 2021

Treatment of elderly patients with neoplasia is challenging. Age is a known prognostic factor in ovarian cancer but the optimal treatment of elderly patients has not been determined. We undertook a retrospective analysis to determine clinical practic...

  • Communication
  • Open Access
2,477 Views
6 Pages

4 March 2021

Uncertainty exists around the need to include an anthracycline if taxane-based adjuvant chemotherapy is being used for human epidermal growth factor receptor-2 (HER2) negative and axillary lymph node negative (LNN) breast cancer. We identified all pa...

  • Article
  • Open Access
3 Citations
2,311 Views
12 Pages

2 March 2021

Background: There is a lack of consensus in current practice guidelines regarding routine neuroimaging in patients with stage IV non-small cell lung cancer (NSCLC) without neurologic symptoms, and there is a paucity of data on the impact of such imag...

  • Guidelines
  • Open Access
7 Citations
3,171 Views
11 Pages

1 March 2021

Objective: To provide recommendations on systemic therapy options in consolidation or maintenance therapy for women with newly diagnosed stage II, III, or IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma including all histological...

  • Systematic Review
  • Open Access
16 Citations
4,876 Views
20 Pages

Comparative Efficacy and Safety of Immunotherapeutic Regimens with PD-1/PD-L1 Inhibitors for Previously Untreated Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis

  • Koichi Ando,
  • Ryo Manabe,
  • Yasunari Kishino,
  • Sojiro Kusumoto,
  • Toshimitsu Yamaoka,
  • Akihiko Tanaka,
  • Tohru Ohmori,
  • Tsukasa Ohnishi and
  • Hironori Sagara

27 February 2021

Improving therapeutic strategies for extensive-stage small cell lung cancer (ES-SCLC) remains a challenge. To date, no reports have directly compared the efficacy and safety of immune checkpoint inhibitors plus platinum–etoposide (ICIs+EP) with plati...

  • Article
  • Open Access
10 Citations
3,185 Views
11 Pages

Improvement of EGFR Testing over the Last Decade and Impact of Delaying TKI Initiation

  • Félix Blanc-Durand,
  • Marie Florescu,
  • Mustapha Tehfe,
  • Bertrand Routy,
  • Raafat Alameddine,
  • Danh Tran-Thanh and
  • Normand Blais

26 February 2021

Background: Epidermal growth factor receptor (EGFR) is the most common oncogenic mutation in lung adenocarcinoma and tyrosine kinase inhibitors (TKIs) have been considered standard treatment for more than a decade. However, time to initiation of TKIs...

  • Article
  • Open Access
2 Citations
3,990 Views
11 Pages

Clinician Perspectives of COVID-19-Related Cancer Drug Funding Measures in Ontario

  • Rohini D. Naipaul,
  • Rebecca E. Mercer,
  • Kelvin K. W. Chan,
  • Lyndee Yeung,
  • Leta Forbes and
  • Scott Gavura

26 February 2021

The COVID-19 pandemic has a significant impact on cancer patients and the delivery of cancer care. To allow clinicians to adapt treatment plans for patients, Ontario Health (Cancer Care Ontario) issued a series of interim funding measures for the pro...

  • Article
  • Open Access
4 Citations
3,937 Views
10 Pages

From Theory to Practice: Bone Health in Women with Early Breast Cancer Treated with Aromatase Inhibitors

  • Leonor Vasconcelos de Matos,
  • Leonor Fernandes,
  • Maria Teresa Neves,
  • Fátima Alves,
  • Mafalda Baleiras,
  • André Ferreira,
  • Pedro Giesteira Cotovio,
  • Tiago Dias Domingues,
  • Mariana Malheiro and
  • Ana Martins
  • + 2 authors

26 February 2021

Aromatase inhibitors (AI) are extensively used as adjuvant endocrine therapy in post-menopausal women with hormone receptor-positive early breast cancer (HR+ EBC), but their impact on bone health is not negligible. This work aimed to assess bone loss...

  • Review
  • Open Access
39 Citations
9,225 Views
17 Pages

The Advances and Challenges of NK Cell-Based Cancer Immunotherapy

  • Synat Kang,
  • Xuefeng Gao,
  • Li Zhang,
  • Erna Yang,
  • Yonghui Li and
  • Li Yu

26 February 2021

Natural killer (NK) cells can be widely applied for cancer immunotherapy due to their ability to lyse tumor targets without prior sensitization or human leukocyte antigens-matching. Several NK-based therapeutic approaches have been attempted in clini...

  • Commentary
  • Open Access
2 Citations
2,499 Views
3 Pages

25 February 2021

For a patient to be effective as a “patient representative” within a health-related organization, work and more than just accepting an honorific title is required. I argue that for a patient to be most effective as a patient representative requires d...

  • Feature Paper
  • Review
  • Open Access
16 Citations
6,509 Views
14 Pages

A Review of Canadian Cancer-Related Clinical Practice Guidelines and Resources during the COVID-19 Pandemic

  • Eliya Farah,
  • Rami Ali,
  • Parker Tope,
  • Mariam El-Zein,
  • Eduardo L. Franco and
  • McGill Task Force on COVID-19 and Cancer

25 February 2021

(1) Background: Preventive measures taken in response to the coronavirus disease 2019 (COVID-19) pandemic have adversely affected an entire range of cancer-related medical activities. The reallocation of medical resources, staff, and ambulatory servi...

  • Article
  • Open Access
17 Citations
3,111 Views
11 Pages

Higher Efficiency of Percutaneous Microwave (MWA) Than Radiofrequency Ablation (RFA) in Achieving Complete Response in Cirrhotic Patients with Early Hepatocellular Carcinoma

  • Silvia Gaia,
  • Michela Ciruolo,
  • Davide Giuseppe Ribaldone,
  • Emanuela Rolle,
  • Enrica Migliore,
  • Elena Mosso,
  • Simone Vola,
  • Alessandra Risso,
  • Sharmila Fagoonee and
  • Patrizia Carucci
  • + 1 author

25 February 2021

Background: Contrasting data are available in the literature regarding the superiority of percutaneous microwave ablation (MWA) or radiofrequency ablation (RFA) in very early or early (BCLA 0 or A) hepatocellular carcinoma (HCC). Aims: The primary ou...

Get Alerted

Add your email address to receive forthcoming issues of this journal.

XFacebookLinkedIn
Curr. Oncol. - ISSN 1718-7729